Full text is available at the source.
Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin
Designed microbial systems for efficient production of psilocybin and psilocin
AI simplified
Abstract
De novo biosynthesis of psilocybin achieved 557.91 mg/L in shake flasks and 2.00 g/L in a bioreactor.
- Psychedelic-assisted therapy may be a promising option for treating depression.
- Psilocybin, found in magic mushrooms, is recognized for its effectiveness against PTSD and treatment-resistant depression.
- Current methods for extracting psilocybin are costly due to its low natural abundance.
- Artificial biosynthetic pathways in Escherichia coli could improve psilocybin production by bypassing a key enzyme.
- This approach may enhance the efficiency and commercial viability of psilocybin production.
AI simplified